J Gastroenterol Hepatol. 2008;23(8 Pt 1):1287-91.
Effect of the CYP2C19 polymorphism on the eradication rate of Helicobacter pylori infection by 7-day triple therapy with regular proton pump inhibitor dosage.
제1저자 강정묵 · 교신저자 김나영
소속 (1)
- Department of Internal Medicine and Liver Research Institute, Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea.
Abstract
BACKGROUND AND AIM Proton pump inhibitors (PPI) are mainly metabolized by cytochrome P450 2C19 (CYP2C19) in the liver. We investigated whether the CYP2C19 genotype plays a role in the eradication rate of Helicobacter pylori (H. pylori) infection in patients receiving pantoprazole- or esomeprazole-based triple therapy.
METHODS A total of 327 patients infected with H. pylori were treated with either pantoprazole or esomeprazole, plus amoxicillin and clarithromycin for 7 days. The presence of the CYP2C19 genotype was determined by pyrosequencing.
RESULTS The overall H. pylori eradication rate was 85%; 82.6% for the PAC regimen, and 88.3% for the EAC regimen; the differences were not statistically significant. The overall eradication rate in the poor metabolizer groups (PM) was significantly higher than in the extensive metabolizer groups (EM) (97.4% vs 83.3%; P = 0.016). The eradication rates in the EM and PM groups were 80.8% and 95.7% for the PAC regimen and 86.8% and 100% for the EAC regimen, respectively.
CONCLUSION The results of this study suggest that the CYP2C19 genotype status may play a role in the H. pylori eradication rate in patients receiving pantoprazole or esomeprazole-based triple therapy.
Comment · 정정
그 밖의 정보
- 출판 형태
- Journal Article, Research Support, Non-U.S. Gov't
- 저널
- Journal of gastroenterology and hepatology · eISSN 1440-1746
- 전자 출판
- 2008-07-10
- MeSH
- 2-Pyridinylmethylsulfinylbenzimidazoles / administration & dosage · Adult · Amoxicillin / administration & dosage · Anti-Bacterial Agents / administration & dosage · Aryl Hydrocarbon Hydroxylases / genetics · Clarithromycin / administration & dosage · Cytochrome P-450 CYP2C19 · Drug Therapy, Combination · Esomeprazole / administration & dosage · Female · Helicobacter Infections / drug therapy / genetics · Helicobacter pylori* · Humans · Male · Middle Aged · Pantoprazole · Polymorphism, Genetic · Proton Pump Inhibitors / administration & dosage · Treatment Outcome
- Substances
- 2-Pyridinylmethylsulfinylbenzimidazoles · Anti-Bacterial Agents · Proton Pump Inhibitors · Amoxicillin · Pantoprazole · Aryl Hydrocarbon Hydroxylases · CYP2C19 protein, human · Cytochrome P-450 CYP2C19 · Clarithromycin · Esomeprazole